The 2018 results from the National Institute on Drug Abuse and University of Michigan's annual drug abuse survey, Monitoring the Future, show that the percentage of teens using OTC cough medicine containing dextromethorphan to get high remains at three percent.
Herein CHPA provides feedback on FDA’s recent draft guidance document addressing the labeling of dietary supplements containing live microbials (also referred to as probiotics).
Yesterday, Pennsylvania Governor Tom Wolf signed into law HB 1951, legislation prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors.
In a study newly published in the medical journal Clinical Toxicology, “therapeutic misuse” of OTC combination products containing acetaminophen was infrequent and declined over a 10-year period.
The proper application/usage, scope, and cause for revisions of the <661> suite of chapters is not clear nor intuitive which is a concern given the potential impact.
The dietary supplement industry’s self-regulatory coalition, the SIDI Work Group, today released an updated version of the Standardized Information on Dietary Ingredients (SIDI TM) Protocol.
CHPA applauds Colorado for enacting a law prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors this week.
CHPA applauds the House of Representatives’ passage of legislation that will restore consumers’ ability to use their HSAs and FSAs to purchase over-the-counter medicines and feminine hygiene products.
CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.
Millions of American families rely on FSAs, HSAs, and other tax-preferred accounts to help meet their basic healthcare needs, including the purchase of OTC medicines.
